Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13104MR)

This product GTTS-WQ13104MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13104MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7024MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ11757MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ8650MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ4636MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ9674MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ13152MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ15209MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ528MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW